کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2906172 | 1173443 | 2006 | 9 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Incorporating Anti-IgE (Omalizumab) Therapy Into Pulmonary Medicine Practice : Practice Management Implications Incorporating Anti-IgE (Omalizumab) Therapy Into Pulmonary Medicine Practice : Practice Management Implications](/preview/png/2906172.png)
Despite aggressive therapy, many asthma patients cannot achieve optimal control, and it is recognized that a small number of patients, generally those with severe persistent asthma, are the most difficult to control and are responsible for a large segment of the costs of asthma. These patients demonstrate a need for additional therapeutic options to achieve enhanced asthma control. Omalizumab should be considered a second-line therapy for patients with moderate-to-severe persistent allergic asthma not fully controlled on standard therapy. This article should not be considered a complete guide to incorporating this therapy into practice but serve as an introduction and a basic review of the practice management aspects of therapy for physicians practicing in the United States.
Journal: Chest - Volume 129, Issue 2, February 2006, Pages 466–474